Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia.

/by

Authors: Glenn Schwarcz, Basawaraj Karajgi, Richard McCarthy
Journal of Clinical Psychopharmacology, June 2009
—
We are reporting improvement of symptoms of schizophrenia in a small group of patients who received the cannabinoid agonist dronabinol (synthetic Delta-9-tetrahydrocannabinol). Before this report, cannabinoids had usually been associated with worsening of psychotic symptoms. I…

Read more

The emerging role of the endocannabinoid system in cardiovascular disease.

/by

Authors: Pál Pacher, Sabine Steffens
Seminars in Immunopathology, June 2009
—
Endocannabinoids are endogenous bioactive lipid mediators present both in the brain and various peripheral tissues, which exert their biological effects via interaction with specific G-protein-coupled cannabinoid receptors, the CB(1) and CB(2). Pathological overactivation of t…

Read more